The Europe carrier screening market is projected to reach USD 821.0 million by 2031, expanding at a 11.9% compound annual growth rate from 2026 to 2033, according to a ResearchAndMarkets.com report added to its offering on Sept. 23, 2026. Growth is being supported by awareness of inherited genetic disorders, demand for preventive reproductive care, advances in molecular diagnostics and wider use of expanded carrier screening panels. The market is shifting from biochemical assays and single-gene analysis toward polymerase chain reaction, microarrays and next-generation sequencing, enabling broader variant detection and reducing reliance on ethnicity-based screening. Expanded carrier screening led the market by type in 2025 and is expected to remain dominant through 2033, while DNA sequencing led technology and laboratories held the largest end-use share. Germany was the leading country market in 2025 and is forecast to retain that position.